Frequency of Positive Anti-CCP Antibodies in Patients of Rheumatoid Arthritis with Negative Rheumatoid Factor: A Cross-sectional Retrospective Data-based Study
Citation Information :
Butt NI, Ghoauri MS. Frequency of Positive Anti-CCP Antibodies in Patients of Rheumatoid Arthritis with Negative Rheumatoid Factor: A Cross-sectional Retrospective Data-based Study. Indian J Med Biochem 2024; 28 (3):72-75.
Objective: To investigate the frequency of positive anti-cyclic citrullinated peptide (CCP) antibodies in rheumatoid arthritis (RA) patients with negative rheumatoid factor (RF) from Lahore, Pakistan.
Materials and methods: This retrospective cross-sectional observational study was conducted at the Department of Medicine and Allied, Azra Naheed Medical College, Superior University Lahore. The 2010 ACR Diagnostic Criteria were used to define RA. The medical records of all patients with RF-negative RA from January 2022 to December 2023 were included in the study. Patients with incomplete data and seronegative arthritis due to other causes were excluded from the study. Retrospective data of 78 RF-negative RA patients, including basic, demographic, and clinical information such as age, sex, anti-CCP antibody status, and disease severity, were assessed and recorded. Statistical Package for the Social Sciences (SPSS) version 26 was used for data entry and analysis.
Results: The mean age was 43.8 ± 15.8 years with 10 (12.8%) males and 68 (87.2%) females. Mean duration of disease was 9.1 ± 7.8 years with 62 (79.5%) patients have disease duration more than 3 years. Mean DAS-28 score was 4.5 ± 1.7 with 48 (61.5%) patients having active disease (DAS-28 score >3.2). Anti-CCP antibodies were observed in 32 patients (41.0%). Stratification of data with regard to anti-CCP antibodies revealed a significant association with sex but not with age, duration of disease, or disease severity.
Conclusion: More than one-third of RA patients with negative RF test results had positive anti-CCP antibodies.
Benahmed D, Abbadi M, Zaoui D, et al. Tumor necrosis factor alpha induced protein 3, interleukin 10, tumor necrosis factor alpha, and interleukin 17 F genes polymorphisms in Algerian patients with rheumatoid arthritis. Mol Biol Rep 2024;51(1):545. DOI: 10.1007/s11033-024-09525-2.
Butt NI, Rasheed MB, Ghoauri MSA, et al. Prevalence of carpal tunnel syndrome in patients with rheumatoid arthritis and its association with disease severity. Pak J Phsyiol 2023;19(4):32–35.
Qaiser F, Masood A, Ujala S. Frequency of positive anti-CCP antibodies in rheumatoid arthritis patients with negative rheumatoid factor. J Islamabad Med Dental Coll 2023;12(4):242–247. DOI: 10.35787/jimdc.v12i4.665.
Lina G, Cuixin Q, Xia Z, et al. CCR9+CD4+ T cells are associated with disease activity in patients with rheumatoid arthritis. Medicine (Baltimore) 2024;103(16):e37803. DOI: 10.1097/MD.0000000000037803.
Khan Tareen MQ, Butt NI, Khan S, et al. Neutrophil lymphocyte ratio as an inflammatory marker in rheumatoid arthritis. PAFMJ 2023;73(5):1509–1512. DOI: 10.51253/pafmj.v73i5.7588.
Yang Z, Bai G, Ding H, et al. Development and validation of the rheumatoid arthritis scale among the system of quality of life instruments for chronic diseases QLICD-RA (V2.0). Sci Rep 2024;14(1):8954. DOI: 10.1038/s41598-024-58910-1.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012;51 Suppl 6:vi5–9. DOI: 10.1093/rheumatology/kes279.
Elghali M, Bannour I, Touil I, et al. Increased Rheumatoid Factor production in patients with severe COVID-19. Diagn Microbiol Infect Dis 2024;109(3):116284. DOI: 10.1016/j.diagmicrobio.2024.116284.
Ashfaq F, Butt NI, Mahmood K, et al. Does vitamin D deficiency affect severity of rheumatoid arthritis? RMJ 2023;48(4):830–834.
de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol 2019;59(1):2. DOI: 10.1186/s42358-018-0042-8.
Aggarwal R, Liao K, Nair R, et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61(11):1472–1483. DOI: 10.1002/art.24827.
Szekanecz Z, Szabó Z, Zeher M, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 2013;56(2–3):439–443. DOI: 10.1007/s12026-013-8425-8.
Zhu JN, Nie LY, Lu XY, et al. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? Clin Chem Lab Med 2019;57(11):1668–1679. DOI: 10.1515/cclm-2019-0167.
Hammam N, El-Husseiny PN, Al-Adle SS, et al. Clinical implications of seropositive and seronegative autoantibody status in rheumatoid arthritis patients: A comparative multicentre observational study. Rheumatol Immunol Res 2024;5(1):57–65. DOI: 10.1515/rir-2024-0007.
van Riel PL, Renskers L. The disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol 2016; 34(5 Suppl 101):S40–S44.
Jiang Y, Li Z, Li Z, Shi X, Chang L, Yan C. Performance evaluation of newly-developed tumor markers assay kit based on flow fluorescence assay. Clin Lab 2024;70(4). DOI: 10.7754/Clin.Lab.2023.230813.
Korpilähde T, Heliövaara M, Kaipiainen-Seppänen O, et al. Regional differences in Finland in the prevalence of rheumatoid factor in the presence and absence of arthritis. Ann Rheum Dis 2003;62(4):353–355. DOI: 10.1136/ard.62.4.353.
Zhao J, Xu L, Wei K, et al. Identification of clinical characteristics biomarkers for rheumatoid arthritis through targeted DNA methylation sequencing. Int Immunopharmacol 2024;131:111860. DOI: 10.1016/j.intimp.2024.111860.
van Wesemael TJ, Ajeganova S, Humphreys J, et al. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: A multicenter cohort study. Arthritis Res Ther 2016;18(1):285. DOI: 10.1186/s13075-016-1177-9.
Di Matteo A, Mankia K, Garcia-Montoya L, et al. Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test. RMD Open 2024;10(2):e003927. DOI: 10.1136/rmdopen-2023-003927.
Butt NI, Ashfaq F, Habib O, et al. Clinico-demographic differences and severity of rheumatoid arthritis. Professional Med J 2023;30(03):342–347. DOI: 10.29309/TPMJ/2023.30.03.7319.
Eker YÖ, Pamuk ÖN, Pamuk GE, et al. The frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: a comparative study. Eur J Rheumatol 2014;1(2):67–71. DOI: 10.5152/eurjrheumatol.2014.022.
Korkmaz C, Us T, Kaşifoğlu T, et al. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 2006;39(10):961–965. DOI: 10.1016/j.clinbiochem.2006.06.004.
Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999;42(3):415–420. DOI: 10.1002/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z.
Hajiesmaeili Y, Tamhankar P, Stranges S, et al. Factors associated with incident cardiovascular disease in patients with rheumatoid arthritis: A scoping review. Autoimmun Rev 2024;23(5):103539. DOI: 10.1016/j.autrev.2024.103539.
Keleşoğlu Dinçer AB, Şahan HF. Increased epicardial adipose tissue thickness as a sign of subclinical atherosclerosis in patients with rheumatoid arthritis and its relationship with disease activity indices. Intern Emerg Med 2024. DOI: 10.1007/s11739-024-03542-6.